Biote Names Robert Peterson as Chief Financial Officer
2024年1月12日 - 6:05AM
ビジネスワイヤ(英語)
biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a
leading solutions provider in preventive health care through the
delivery of personalized hormone optimization and therapeutic
wellness, today announced that Robert Peterson has been named Chief
Financial Officer, effective January 8, 2024. Mr. Peterson will
lead Biote’s finance operations, including accounting and
controllership, financial planning and analysis, financial
reporting, internal audit, tax, treasury and investor relations.
Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue
other opportunities, but will remain as an advisor to the Company
during a transition period. Mr. Kamdar’s transition is unrelated to
the Company’s financial results or any disagreement with the
Company over its accounting principles, practices or financial
disclosures.
Mr. Peterson brings 15 years of health and wellness industry
experience as well as public company experience to Biote. Prior to
joining the Company, he served as Executive Vice President, Chief
Financial Officer of Virbac Corporation, a subsidiary of Virbac
S.A., a global veterinary pharmaceutical and wellness company.
Additionally, he spent eight years at Alcon Laboratories/Novartis
Eye Care, where he held roles of progressive responsibility,
including Global Head of Business Planning and Analysis as well as
Finance Manager Investor Relations.
Terry Weber, Biote Chief Executive Officer, said, “Bob is a
proven and highly accomplished finance executive, with a record of
driving successful financial and operational performance across
organizations. His extensive experience and deep expertise in
financial planning and analysis will be instrumental as we execute
on our strategic vision to become the leading provider of
evidence-based therapeutic wellness solutions.”
Ms. Weber continued, “I appreciate Samar’s assistance in
ensuring a smooth transition period. On behalf of our Board of
Directors, I want to thank Samar for his valuable contributions and
wish him the best in his future endeavors.”
Mr. Peterson commented, “I am pleased to join Biote at this
pivotal time as the company continues to expand into the growing
market for therapeutic wellness. I look forward to working with
Biote’s management team to maximize our growth opportunities,
further our operating efficiencies and deliver on our financial
objectives.”
About Biote
Biote is transforming healthy aging through innovative,
personalized hormone optimization and therapeutic wellness
solutions delivered by Biote-certified medical providers. Biote
trains practitioners to identify and treat early indicators of
aging conditions, an underserved global market, providing
affordable symptom relief for patients and driving clinic success
for practitioners.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Some of the forward-looking statements can be identified
by the use of forward-looking words. Statements that are not
historical in nature, including the words “may,” “can,” “should,”
“will,” “estimate,” “plan,” “project,” “forecast,” “intend,”
“expect,” “anticipate,” “hope,” “anticipate,” “believe,” “seek,”
“target,” “continue,” “could,” “might,” “ongoing,” “potential,”
“predict,” “would” and other similar expressions, are intended to
identify forward-looking statements. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual results or developments to differ materially from
those expressed or implied by such forward-looking statements,
including but not limited to: the success of our dietary
supplements to attain significant market acceptance among clinics,
practitioners and their patients; our customers’ reliance on
certain third parties to support the manufacturing of bio-identical
hormones for prescribers; our and our customers’ sensitivity to
regulatory, economic, environmental and competitive conditions in
certain geographic regions; our ability to increase the use by
practitioners and clinics of the Biote Method at the rate that we
anticipate or at all; our ability to grow our business; the
significant competition we face in our industry; the impact of
strategic acquisitions and the implementation of our growth
strategies; our limited operating history; our ability to protect
our intellectual property; the heavy regulatory oversight in our
industry; changes in applicable laws or regulations; the inability
to profitably expand in existing markets and into new markets; the
possibility that we may be adversely impacted by other economic,
business and/or competitive factors, including recent bank
failures; and future exchange and interest rates. The foregoing
list of factors is not exhaustive. You should carefully consider
the risks and uncertainties described in the “Risk Factors” section
of the Biote’s Quarterly Report on Form 10-Q for the fiscal quarter
ended September 30, 2023 and other documents filed by Biote from
time to time with the Securities and Exchange Commission. These
filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Biote assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Biote does
not give any assurance that it will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240111365529/en/
Investor Relations: Eric Prouty AdvisIRy Partners
eric.prouty@advisiry.com Media: Press@biote.com
Biote (NASDAQ:BTMD)
過去 株価チャート
から 12 2024 まで 1 2025
Biote (NASDAQ:BTMD)
過去 株価チャート
から 1 2024 まで 1 2025